Vir Biotechnology (VIR) Accumulated Expenses (2018 - 2026)

Vir Biotechnology's Accumulated Expenses history runs 9 years deep, the most recent figure standing at $68.1 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 34.59% year-over-year to $68.1 million; the TTM figure through Mar 2026 stood at $68.1 million (down 34.59% YoY), while the FY2025 annual figure was $83.0 million, down 15.74% from the prior year.
• Accumulated Expenses came in at $68.1 million for Q1 2026 at Vir Biotechnology, down from $83.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $489.1 million in Q4 2022 to a low of $7.7 million in Q1 2022.
• A 5-year average of $130.8 million and a median of $83.0 million in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses plunged 89.01% in 2022 and surged 5821.06% in 2023, its largest moves.
• Vir Biotechnology's Accumulated Expenses stood at $489.1 million in 2022, then slumped by 78.69% to $104.2 million in 2023, then retreated by 5.47% to $98.5 million in 2024, then retreated by 15.74% to $83.0 million in 2025, then retreated by 17.95% to $68.1 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $68.1 million, $83.0 million, and $68.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison